Abstract
Insulin-like growth factor (IGF) plays an important role in tissue growth and development. Several studies have demonstrated the association between circulating levels of IGF-1 and -2 and cancer risk, and the IGF system has been implicated in the oncogenesis of essentially all solid and hematologic malignancies. The optimal strategy for targeting IGF signaling in patients with cancer is not clear. The modest benefits reported thus far underscore the need for a better understanding of IGF signaling, which would enable clinicians to identify the subset of patients with the greatest likelihood of attaining benefit from this targeted approach.
Copyright © 2012 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Breast Neoplasms / blood
-
Breast Neoplasms / metabolism
-
Cell Proliferation
-
Cell Survival / physiology
-
Female
-
Glioma / blood
-
Glioma / metabolism
-
Humans
-
Insulin-Like Growth Factor Binding Proteins / physiology
-
Insulin-Like Growth Factor I / metabolism*
-
Insulin-Like Growth Factor II / metabolism*
-
Lung Neoplasms / blood
-
Lung Neoplasms / metabolism
-
Neoplasms / blood
-
Neoplasms / metabolism*
-
Ovarian Neoplasms / blood
-
Ovarian Neoplasms / metabolism
-
Receptor, Insulin / physiology
-
Risk
-
Sarcoma / blood
-
Sarcoma / metabolism
-
Signal Transduction / physiology
Substances
-
Insulin-Like Growth Factor Binding Proteins
-
Insulin-Like Growth Factor I
-
Insulin-Like Growth Factor II
-
Receptor, Insulin